BMN 270: Preliminary Phase I/II data

Preliminary data from the first 8 patients with severe hemophilia A in an open-label, dose-escalation, U.K. Phase I/II trial showed that a single IV infusion of BMN 270 improved disease severity per

Read the full 329 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE